세계의 항체 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2030년)

The global demand for Antibody Therapeutics Market is presumed to reach the market size of nearly USD 804.38 BN by 2030 from USD 259.14 BN in 2022 with a CAGR of 15.21% under the study period 2023 - 2030.

Antibody therapeutics, also known as therapeutic antibodies or biological drugs, are a class of medications developed from antibodies produced by the immune system. These antibodies can be engineered or derived from animals, primarily mice or rabbits, and then modified to be used as treatments for various diseases.

MARKET DYNAMICS

The Antibody therapeutics market is driven by various factors contributing to its substantial growth. Increasing incidences of chronic diseases like cancer, autoimmune disorders, and infectious ailments fuel the demand for precise, targeted treatments that antibody therapies offer. Advancements in biotechnology, particularly in antibody engineering and manufacturing, lead to more effective and safer therapies, expanding their applications across diverse medical fields. Investments in research and development, especially in exploring new targets and innovative antibody formats, further propel market expansion. The shift toward personalized medicine favors antibody therapeutics, allowing tailored treatments for individual patients. Successful clinical trials and regulatory approvals bolster confidence in these therapies among healthcare professionals and patients, driving adoption rates. Rising healthcare expenditure, collaborations among industry players, and the broadening scope of antibody-based treatments in various medical domains collectively contribute to the robust growth of the Antibody therapeutics market, positioning these therapies at the forefront of modern medicine.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antibody therapeutics. The growth and trends of antibody therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the antibody therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Format

• Monoclonal Antibody
• Polyclonal Antibody Therapy
• Bispecific Antibody
• Antibody Fragment
• Other

By Disease Areas

• Autoimmune & Inflammatory Diseases
• Oncology
• Hematology
• Infectious Diseases
• Osteology
• Immunology
• Neurology
• Other

By Route Of Administration

• Intravenous
• Subcutaneous
• Other

By Source

• Human
• Humanized
• Chimeric
• Other

By End User

• Hospitals
• Long-Term Care Facilities
• Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antibody Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antibody Therapeutics market include F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ANTIBODY THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Format
  • 3.7.2 Market Attractiveness Analysis By Disease Areas
  • 3.7.3 Market Attractiveness Analysis By Route Of Administration
  • 3.7.4 Market Attractiveness Analysis By Source
  • 3.7.5 Market Attractiveness Analysis By End User
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY FORMAT

• 5.1 Overview by Format
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Format
• 5.4 Monoclonal Antibody Historic and Forecast Sales by Regions
• 5.5 Polyclonal Antibody Therapy Historic and Forecast Sales by Regions
• 5.6 Bispecific Antibody Historic and Forecast Sales by Regions
• 5.7 Antibody Fragment Historic and Forecast Sales by Regions
• 5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY DISEASE AREAS

• 6.1 Overview by Disease Areas
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Disease Areas
• 6.4 Autoimmune & Inflammatory Diseases Historic and Forecast Sales by Regions
• 6.5 Oncology Historic and Forecast Sales by Regions
• 6.6 Hematology Historic and Forecast Sales by Regions
• 6.7 Infectious Diseases Historic and Forecast Sales by Regions
• 6.8 Osteology Historic and Forecast Sales by Regions
• 6.9 Immunology Historic and Forecast Sales by Regions
• 6.10. Neurology Historic and Forecast Sales by Regions
• 6.11 Other Historic and Forecast Sales by Regions

7 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1 Overview by Route Of Administration
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Route Of Administration
• 7.4 Intravenous Historic and Forecast Sales by Regions
• 7.5 Subcutaneous Historic and Forecast Sales by Regions
• 7.6 Other Historic and Forecast Sales by Regions

8 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY SOURCE

• 8.1 Overview by Source
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Source
• 8.4 Human Historic and Forecast Sales by Regions
• 8.5 Humanized Historic and Forecast Sales by Regions
• 8.6 Chimeric Historic and Forecast Sales by Regions
• 8.7 Other Historic and Forecast Sales by Regions

9 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY END USER

• 9.1 Overview by End User
• 9.2 Historical and Forecast Data
• 9.3 Analysis by End User
• 9.4 Hospitals Historic and Forecast Sales by Regions
• 9.5 Long-term Care Facilities Historic and Forecast Sales by Regions
• 9.6 Other Historic and Forecast Sales by Regions

10 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2. North America By Segment Sales Analysis
  • 10.3.3. North America By Country Sales Analysis
  • 10.3.4. United State Sales Analysis
  • 10.3.5. Canada Sales Analysis
  • 10.3.6. Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2. Europe by Segment Sales Analysis
  • 10.4.3. Europe by Country Sales Analysis
  • 10.4.4. United Kingdom Sales Analysis
  • 10.4.5. France Sales Analysis
  • 10.4.6. Germany Sales Analysis
  • 10.4.7. Italy Sales Analysis
  • 10.4.8. Russia Sales Analysis
  • 10.4.9. Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2. Asia Pacific by Segment Sales Analysis
  • 10.5.3. Asia Pacific by Country Sales Analysis
  • 10.5.4. China Sales Analysis
  • 10.5.5. India Sales Analysis
  • 10.5.6. Japan Sales Analysis
  • 10.5.7. South Korea Sales Analysis
  • 10.5.8. Australia Sales Analysis
  • 10.5.9. South East Asia Sales Analysis
  • 10.5.10. Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2. Latin America by Segment Sales Analysis
  • 10.6.3. Latin America by Country Sales Analysis
  • 10.6.4. Brazil Sales Analysis
  • 10.6.5. Argentina Sales Analysis
  • 10.6.6. Peru Sales Analysis
  • 10.6.7. Chile Sales Analysis
  • 10.6.8. Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2. Middle East & Africa by Segment Sales Analysis
  • 10.7.3. Middle East & Africa by Country Sales Analysis
  • 10.7.4. Saudi Arabia Sales Analysis
  • 10.7.5. UAE Sales Analysis
  • 10.7.6. Israel Sales Analysis
  • 10.7.7. South Africa Sales Analysis
  • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ANTIBODY THERAPEUTICS COMPANIES

• 11.1. Antibody Therapeutics Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12 . COMPANY PROFILES OF ANTIBODY THERAPEUTICS INDUSTRY

• 12.1. Company Share Analysis
• 12.2. Market Concentration Rate
• 12.3. F. Hoffmann-La Roche Ltd. (Switzerland)
  • 12.3.1. Company Overview
  • 12.3.2. Company Revenue
  • 12.3.3. Products
  • 12.3.4. Recent Developments
• 12.4. AbbVie Inc. (US)
  • 12.4.1. Company Overview
  • 12.4.2. Company Revenue
  • 12.4.3. Products
  • 12.4.4. Recent Developments
• 12.5. Johnson & Johnson (US)
  • 12.5.1. Company Overview
  • 12.5.2. Company Revenue
  • 12.5.3. Products
  • 12.5.4. Recent Developments
• 12.6. Merck KGaA (Germany)
  • 12.6.1. Company Overview
  • 12.6.2. Company Revenue
  • 12.6.3. Products
  • 12.6.4. Recent Developments
• 12.7. Bristol-Myers Squibb (US)
  • 12.7.1. Company Overview
  • 12.7.2. Company Revenue
  • 12.7.3. Products
  • 12.7.4. Recent Developments
• 12.8. AstraZeneca (UK)
  • 12.8.1. Company Overview
  • 12.8.2. Company Revenue
  • 12.8.3. Products
  • 12.8.4. Recent Developments
• 12.9. Sanofi (France)
  • 12.9.1. Company Overview
  • 12.9.2. Company Revenue
  • 12.9.3. Products
  • 12.9.4. Recent Developments
• 12.10. Regeneron Pharmaceuticals Inc. (US)
  • 12.10.1. Company Overview
  • 12.10.2. Company Revenue
  • 12.10.3. Products
  • 12.10.4. Recent Developments
• 12.11. Novartis AG (Switzerland)
  • 12.11.1. Company Overview
  • 12.11.2. Company Revenue
  • 12.11.3. Products
  • 12.11.4. Recent Developments
• 12.12. Amgen Inc. (US)
  • 12.12.1. Company Overview
  • 12.12.2. Company Revenue
  • 12.12.3. Products
  • 12.12.4. Recent Developments
• 12.13. Biogen Inc. (US)
  • 12.13.1. Company Overview
  • 12.13.2. Company Revenue
  • 12.13.3. Products
  • 12.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies